Molecular Cancer Therapeutics | American Association for Cancer Research

Skip Nav Destination

Current Issue

Volume 21,

Issue 5

1 May 2022

About the Journal

Molecular Cancer Therapeutics publishes articles on the discovery and preclinical development of novel therapeutic agents for oncology, preclinical studies of approved therapeutics, mechanisms of drug action, mechanism of drug resistance, biomarkers of drug response, novel models and technologies, and occasional drug toxicity mechanisms.. Read More About the Journal

Editor-in-Chief

Beverly A Teicher

View Full Editorial Board

Impact Factor

6.261

SUBMIT TO JOURNAL

Featured Articles

Tucatinib has selective activity in HER2-positive cancers and significant combined activity with approved and novel breast cancer targeted therapies

O’Brien et al.

Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma

Javaid et al.

Proteolytic pan-RAS cleavage leads to tumor regression in patient-derived pancreatic cancer xenografts

Vidimar et al.

Trending - Altmetric

Proteolytic pan-RAS Cleavage Leads to Tumor Regression in Patient-derived Pancreatic Cancer Xenografts

Last mentioned on Thursday May 26 2022

Novel Anti-LY6G6D/CD3 T Cell-Dependent Bispecific Antibody for the Treatment of Colorectal Cancer

Last mentioned on Thursday May 26 2022

Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma

Last mentioned on Friday May 27 2022

Optimal Strategy and Benefit of Pulsed Therapy Depend On Tumor Heterogeneity and Aggressiveness at Time of Treatment Initiation

Last mentioned on Friday May 27 2022

CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization

Last mentioned on Thursday May 26 2022

Latest
Most Read
Most Cited

Targeting DUSP activity as a treatment for high grade serous ovarian carcinoma

GAS6-AXL inhibition by AVB-500 overcomes resistance to paclitaxel in endometrial cancer by decreasing tumor cell glycolysis

Pharmacologic Activation of STING in the Bladder Induces Potent Antitumor Immunity in Non–Muscle Invasive Murine Bladder Cancer

PLGA-nano-encapsulated Disulfiram inhibits hypoxia-induced NFκB, cancer stem cells and targets glioblastoma in vitro and in vivo

Tweets by MCT_AACR

About the Journal

Editor-in-Chief

Impact Factor

Featured Articles

Tucatinib has selective activity in HER2-positive cancers and significant combined activity with approved and novel breast cancer targeted therapies

Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma

Proteolytic pan-RAS cleavage leads to tumor regression in patient-derived pancreatic cancer xenografts

Trending - Altmetric

AACR Journals

This Feature Is Available To Subscribers Only